WESTLAKE VILLAGE, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it will advance its program to develop topical roflumilast foam (ARQ-154) as a treatment for seborrheic dermatitis into Phase 3 following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The Phase 3 program will consist of a single pivotal trial, which the Company anticipates initiating in the second or third quarter of 2021. Roflumilast foam is a once-daily topical foam formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor.
News Ticker
- [ March 31, 2023 ] Postdoctoral Fellow – Computational Biology and Molecular Dynamics – City of Hope – Duarte, CA Los Angeles Biotech Jobs
- [ March 31, 2023 ] QC Microbiology Associate II – B. Braun Medical Inc. – Irvine, CA Los Angeles Biotech Jobs
- [ March 31, 2023 ] Associate Director, Bioinformatics Engineering, remote – Quest Diagnostics – San Juan Capistrano, CA Los Angeles Biotech Jobs
- [ March 31, 2023 ] Research Scientist – MicroBio Engineering Inc. – San Luis Obispo, CA Los Angeles Biotech Jobs
- [ March 31, 2023 ] Quality Control Associate – Microbiology – TechTrueUP – Thousand Oaks, CA Los Angeles Biotech Jobs
Copyright © 2021 Biotech Networks, LLC
